INTERVIEW : USA - ANTITRUST - PHARMACEUTICAL IN-HOUSE COUNSEL

Marc BROTMAN, Pfizer: U.S. and global antitrust issues from a pharmaceutical in-house counsel perspective

Interview conducted by Kent Bernard,Fordham School of Law and Anna Pavlik, Institute of Competition Law.

1999 – Present Vice President & Assistant General Counsel, Chief Antitrust Counsel, Pfizer Inc. 1992 – 1999 Associate, Trade Regulation department, Weil Gotshal & Manges LLP 1992 J.D., Columbia University Law School What is your background? I’ve had a focus on antitrust work since starting at Weil Gotshal, with my first large matter being the predatory pricing case that Northwest and Continental Airlines brought against our client American Airlines. I also worked on a trade secret case for Quaker Oats during my tenure there and a number of merger analyses and reviews by the FTC and DOJ. Since coming to Pfizer, in addition to my antitrust work, I’ve provided legal counsel on some of Pfizer’s largest and highest profile medicines and currently support Pfizer’s Corporate Affairs

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Marc Brotman, Marc BROTMAN, Pfizer: U.S. and global antitrust issues from a pharmaceutical in-house counsel perspective, February 2014, Concurrences Review N° 1-2014, Art. N° 62205, pp. 7-9

Visites 595

All reviews